Medical/Pharmaceuticals
Sirtex Medical and BlackSwan Vascular, Inc. announce first patient enrolled in pivotal LAVA Study
LAVA clinical trial underway for potential first FDA-approved liquid embolic system for a peripheral vascular indication WOBURN, Mass., April 20, 2021 /PRNewswire/ -- Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, and BlackSwan Vascular, Inc. (BlackSwan), a B...
2021-04-20 00:57
1741
ASG Superconductors with HZDR combine magnetic resonance imaging with proton therapy
Towards live imaging in cancer therapy GENOA, Italy, April 19, 2021 /PRNewswire/ -- ASG Superconductors with Helmholtz-Zentrum Dresden-Rossendorf (HZDR) will build the world's first prototype that tracks moving tumors with magnetic resonance imaging (MRI) in real time during proton therapy, comb...
2021-04-19 22:56
3027
China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port
HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Rel...
2021-04-19 20:30
3841
CNPharm has succeeded in maintaining IC100 for 24 hours with one injection
- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...
2021-04-19 20:15
2543
Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy
SUZHOU, China, April 19, 2021 /PRNewswire/ -- On April 16, 2021, Suzhou Porton BiologicsLtd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO se...
2021-04-19 20:00
5057
PharmAbcine announces Clinical Trial Collaboration with MSD for the Phase II study in mTNBC
DAEJEON, South Korea, April 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has entered into an agreement with MSD to initiate a Phase II combination trial of olin...
2021-04-19 20:00
1992
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE
SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading ...
2021-04-19 17:54
4147
Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer
SUZHOU, China, April 18, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been success...
2021-04-19 08:00
2035
Adapting to change: sustaining care in a new world
World Hemophilia Day 2021 MONTRÉAL, April 17, 2021 /PRNewswire/ -- April 17, 2021 is World Hemophilia Day. The theme of the event this year is "Adapting to change: sustaining care in a new world". This important event is about bringing the global bleeding disorders community together. With the ...
2021-04-17 17:00
2908
Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC
SEOUL, South Korea and JINAN, China, April 16, 2021 /PRNewswire/ -- Peptron, Inc. ("Peptron", KOSDAQ: 087010), aSouth Korea-based biotech company, and Qilu Pharmaceutical ("Qilu"), a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing and commerc...
2021-04-16 20:00
4781
Kintor Pharmaceuticals Announced Successful Dosing of the First Batch of Patients for Acne Vulgaris Phase I/II Clinical Trial of Pyrilutamide
SUZHOU, China, April 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first b...
2021-04-16 18:29
5928
Report from the Extraordinary General Meeting 2021 in Elekta
STOCKHOLM, April 16, 2021 /PRNewswire/ -- Elekta AB (publ) (EKTA-B.ST) has held an Extraordinary General Meeting on Friday16 April 2021. Due to Covid-19, the Meeting was conducted by advance postal vote, without the physical attendance of shareholders, representatives or third parties. A summary ...
2021-04-16 16:59
7662
GT Apeiron Therapeutics Strengthens Advisory Board
SHANGHAI, April 16, 2021 /PRNewswire/ -- Keith Lenden and Dr. Honggang Bi has been appointed as new members of the Advisory Board at GT Apeiron Therapeutics, an AI empowered drug discovery start-up developing oncology therapeutics. Mr. Lenden and Dr. Bi add further expertise in drug discovery inn...
2021-04-16 09:00
2616
Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting
SUZHOU, China, April 15, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functio...
2021-04-16 08:00
1667
Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
SUZHOU, China, April 15, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from t...
2021-04-15 18:20
6079
Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive
SINGAPORE, April 15, 2021 /PRNewswire/ -- Juniper Biologics, a science-led healthcare company focused on researching, developing & commercialising novel therapies, has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive. Juniper Biologics wi...
2021-04-15 16:30
2719
Mentice appoints Pontus Appelqvist as Vice President and GM for Asia Pacific
STOCKHOLM, April 15, 2021 /PRNewswire/ -- Mentice AB (STO: MNTC), a leading supplier of high-tech solutions for simulation in the medical sector, with a focus on endovascular procedures, today announced the appointment of Pontus Appelqvist as Vice President and General Manager forAsia Pacific. Po...
2021-04-15 16:21
2578
New clinical study shows JOYSBIO COVID-19 neutralizing antibody rapid test nearly 98% accurate in verifying antibodies after vaccination
TIANJIN, China, April 15, 2021 /PRNewswire/ -- In a major breakthrough for testing COVID-19 immunity, JOYSBIO, a Chinese medical device manufacturer, just announced the completion of a clinical study inItaly, showing their COVID-19 neutralizing antibody rapid test kit is 98.05% effective in detec...
2021-04-15 14:20
3332
Seegene's Italy subsidiary secures public procurement for 7.15 million COVID-19 diagnostic tests, the largest tender in history
* Seegene's Italian subsidiary to supply some 7.15 million COVID-19 tests to 17 regions there * S. Korean biotechnology firm to expand its influence in Italy's PCR diagnostic industry SEOUL, South Korea, April 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading molecular diagnostics ...
2021-04-15 14:19
2317
Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
HANGZHOU, China, April 14, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the global phase III clinical trial (BURAN) at Shanghai Eastern Hospital Medical Center inChin...
2021-04-15 09:00
2860
Week's Top Stories
Most Reposted
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
[Picked up by 321 media titles]
2026-04-09 13:00
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
[Picked up by 312 media titles]
2026-04-09 09:00Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
iQIYI to Open Its First Central China Theme Park in Wuhan, Continuing to Bring IP Value Beyond the Screen
[Picked up by 288 media titles]
2026-04-10 11:38
OneQode, Hitachi Vantara & Cylix Form Strategic Alliance to Launch Sovereign AI Factory Initiative
[Picked up by 284 media titles]
2026-04-08 08:00
Most Read
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
2026-04-09 13:00
7459
NYSE Content Update: Starfish Space Adds Over $100 Million in Funding to Boost Growth
2026-04-07 21:06
7282
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
2026-04-09 09:00
6918